



Food and Drug Administration  
 Cincinnati District Office  
 6751 Steger Drive  
 Cincinnati, OH 45237-3097  
 Telephone: (513) 679-2700  
 FAX: (513) 679-2772

## WARNING LETTER

Cin WL -7054-01  
 March 28, 2001

**CERTIFIED MAIL**  
**RETURN RECEIPT REQUESTED**

Mr. Dean Tackett  
 Director of Radiology  
 Hardin Memorial Hospital  
 Radiology Department  
 921 E. Franklin St.  
 Kenton, OH 43326

Facility I.D.#: 158576

Dear Mr. Tackett:

A representative from the State of Ohio acting on behalf of the Food and Drug Administration (FDA) inspected your facility on January 25, 2001. This inspection revealed a serious regulatory problem involving the mammography at your facility.

Under a United States federal law, the Mammography Quality Standards Act (MQSA) of 1992, your facility must meet specific requirements for mammography. These requirements help protect the health of women by assuring that a facility can perform quality mammography. The inspection revealed the following **repeat** Level 2 finding at your facility:

**Quality Assurance – Equipment -21 CFR 900.12(e)(2)(i)-(iv)**

Your records revealed that your facility phantom quality control records for the mammography unit were missing for two weeks. The MQSA regulation requires the mammography unit be evaluated by performing at least weekly the image quality evaluation test. The inspection found that your facility failed to perform this quality control test during the weeks of December 17-23, 2000 and January 15-19, 2001.

The specific problem noted above appeared on your MQSA Facility Inspection Report, which your facility received at the close of the inspection. The problem is identified as **repeat** Level 2 because it identifies a failure to meet a significant MQSA requirement and indicates failure by your facility to implement permanent correction of the problem found during your previous inspection.

Because the condition may be symptomatic of serious underlying problem that could compromise the quality of mammography at your facility, it represents a violation of the law which may result in FDA taking regulatory action without further notice to you. These actions include, but are not limited to, placing your facility under a Directed Plan of Correction, charging your facility for the cost of on-site

monitoring, assessing civil money penalties up to \$10,000 for each failure to substantially comply with, or each day of failure to substantially comply with, MQSA standards, suspension or revocation of your facility's FDA certificate, or obtaining a court injunction against performing further mammography.

In addition, your response should address the **repeat** Level 3 noncompliance items that were listed on the inspection report provided to you at the close of the inspection. These **repeat** Level 3 noncompliance items are:

**Quality Assurance – General - 21 CFR 900.12(d)(2)**

Your records revealed that your facility quality assurance (QA) program written protocol is inadequate. Your written QA protocol lacked the following items: personnel responsibilities and current technique tables/chart.

**Quality Standards – Personnel – 21 CFR 900.12(a)(4)**

The required personnel qualification documents were unavailable during the inspection.

It is necessary for you to act on this matter immediately. Please explain the following elements to this office in writing within fifteen (15) working days from the date you received this letter:

- The specific steps you have taken to correct the violations noted in this letter; and
- Each step your facility is taking **to prevent the recurrence** of similar violations.

Please submit sample records that demonstrate proper record keeping procedures, if the findings relate to quality control or other records (Note: Patient names or identification should be deleted from any copies submitted).

Please submit your response to:

Mr. R. Terry Bolen  
MQSA Compliance Officer  
Food & Drug Administration  
6751 Steger Drive  
Cincinnati, OH 45237-3097  
FAX: 513-679-2772

Also, please send a copy to the State radiation control office:

Ms. Cindy Grant  
Ohio Department of Health  
1 Government Center  
Suite 1320  
Toledo, OH 43604

Finally, you should understand that there are many FDA requirements pertaining to mammography. This letter pertains only to findings of your inspection and does not necessarily address other obligations you have under the law. You may obtain general information about all of FDA's requirements for mammography facilities by contacting the Mammography Quality Assurance Program, Food and Drug Administration, P.O. Box 6057, Columbia, MD 21045-6057 (1-800-838-7715) or through the Internet at <http://www.fda.gov/cdrh/mammography>.

If you have more specific questions about mammography facility requirements, or about the content of this letter, please feel free to contact R. Terry Bolen at 513-679-2700, extension 138

Sincerely yours,

  
Henry L. Fielden  
District Director  
Cincinnati District Office

c.  
OH/CGrant

Priscilla F. Butler, M.S.  
Director, Breast Imaging Accreditation Program  
American College of Radiology  
1891 Preston White Dr.  
Reston, VA 20191